Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | TNNI3 | P19429 | 1/20 | 0.54 |
| ▸ | TNNT2 | P45379 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | GFER | P55789 | 1/20 | 0.54 |
| ▸ | TNNC1 | P63316 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | ALOX5 | P09917 | 12/20 | 0.53 |
| ▸ | MYC | P01106 | 1/20 | 0.44 |
| ▸ | MAX | P61244 | 1/20 | 0.44 |
| ▸ | NAT1 | P18440 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4356501 | 1.00 | POLB (0.60) | POLBMEN1NPC1TNNI3TNNT2 | |
| SCHEMBL4350154 | 0.92 | POLB (0.71) | POLBMEN1NPC1TNNI3TNNT2 | |
| SCHEMBL4350157 | 0.92 | POLB (0.71) | POLBMEN1NPC1TNNI3TNNT2 | |
| Bromide SCHEMBL4362351 | 0.91 | POLB (0.69) | POLBMEN1NPC1TNNI3TNNT2 | |
| Bromide SCHEMBL4362353 | 0.91 | POLB (0.69) | POLBMEN1NPC1TNNI3TNNT2 | |
| SCHEMBL4348545 | 0.85 | RAB9A (0.58) | POLBMEN1NPC1TNNI3TNNT2 | |
| SCHEMBL4348541 | 0.85 | RAB9A (0.58) | POLBMEN1NPC1TNNI3TNNT2 | |
| Bromide SCHEMBL4348012 | 0.84 | RAB9A (0.56) | POLBMEN1NPC1TNNI3TNNT2 | |
| Bromide SCHEMBL4348013 | 0.84 | RAB9A (0.56) | POLBMEN1NPC1TNNI3TNNT2 | |
| SCHEMBL4348992 | 0.84 | MEN1 (0.56) | POLBMEN1NPC1TNNI3TNNT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1890695-B1 | USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS | GRUENENTHAL GMBH (DE) | 2013-02-20 | — | — | EP | claimed |
| US-20090215758-A1 | Use of 2,5-Disubstituted Thiazol-4-One Derivatives in Drugs | GRUENENTHAL GMBH (DE) | 2009-08-27 | — | — | US | claimed |
| EP-1890695-A2 | USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS | Grünenthal GmbH (DE) | 2008-02-27 | — | — | EP | claimed |
| WO-2006122777-A2 | USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS | Grünenthal GmbH (DE) | 2006-11-23 | — | — | WO | claimed |
| EP-1890695-B1 | USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS | GRUENENTHAL GMBH (DE) | 2013-02-20 | — | — | EP | disclosed |
| US-20090215758-A1 | Use of 2,5-Disubstituted Thiazol-4-One Derivatives in Drugs | GRUENENTHAL GMBH (DE) | 2009-08-27 | — | — | US | disclosed |
| EP-1890695-A2 | USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS | Grünenthal GmbH (DE) | 2008-02-27 | — | — | EP | disclosed |
| WO-2006122777-A2 | USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS | Grünenthal GmbH (DE) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215758-A1 | Use of 2,5-Disubstituted Thiazol-4-One Derivatives in Drugs | ABCB1, ABCG2, SLC5A2 | POLB 4427/4885MEN1 1725/4885NPC1 326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.